Figure 1
From: The Kyoto Prognostic Index for patients with diffuse large B-cell lymphoma in the rituximab era
(a, b) OS (a) and PFS (b) of all 465-DLBCL patients analyzed with the Kaplan–Meier method. (c, d) OS (c) and PFS (d) according to the KPI in the training cohort. (e, f) OS (e) and PFS (f) according to the KPI in the validation cohort. *3-year OS (95% CI; %), **3-year PFS (95% CI; %).
